ampelopsin has been researched along with Adverse Drug Event in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bian, W; Guan, X; Jiang, J; Li, W; Sun, Y; Wang, Y; Xu, C; Yu, X; Zhang, C; Zhao, Q | 1 |
1 other study(ies) available for ampelopsin and Adverse Drug Event
| Article | Year |
|---|---|
The mechanism of rh-endostatin-induced cardiotoxicity and its protection by dihydromyricetin[in vivo/in vitro, C57BL/6 mice, AC16 and hiPSC-CMs].
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cardiotoxicity; Drug-Related Side Effects and Adverse Reactions; Endostatins; Humans; Induced Pluripotent Stem Cells; Lung Neoplasms; Mice; Mice, Inbred C57BL; Myocytes, Cardiac | 2023 |